Half of Thermo Fisher's reported revenue growth was bought rather than earned. The company's own non-GAAP reconciliation in the 10-Q splits the second quarter's 10% reported growth into 5 points of organic gain, 5 points from acquisitions and 1 point from currency (components round independently, so they do not sum exactly). That matters because the purchase was expensive: cash fell from $9,852 million at year end to $4,064 million at June 27, and goodwill now stands at 104% of the company's entire book equity, up from 92% at year end. Management nonetheless raised full-year guidance on the July 23 earnings call — revenue to $47.4–48.1 billion and adjusted EPS to $24.93–25.33. The underlying business did improve — organic growth accelerated to 5% in the quarter from 3% across the first half — but investors are now funding that recovery through a far more leveraged balance sheet.
One framing point the headline numbers obscure: Clario Holdings closed on March 24, 2026, four days before the first quarter ended (Note 2). The cash and goodwill damage was therefore booked largely in Q1; Q2 is the first full quarter of Clario revenue and amortization. Every balance-sheet and cash-flow comparison below is a six-month movement, not a three-month one.
1. Balance Sheet
1-1. Major asset movements
Comparisons run from December 31, 2025 (fiscal year end) to June 27, 2026, the standard basis for a 10-Q. All figures are from the condensed consolidated balance sheet.
| Item | Dec 31, 2025 ($M) | Jun 27, 2026 ($M) | Change % |
|---|---|---|---|
| Cash and cash equivalents | 9,852 | 4,064 | -58.8% |
| Short-term investments | 253 | — | -100.0% |
| Accounts receivable, net | 8,900 | 9,451 | +6.2% |
| Inventories | 5,425 | 5,627 | +3.7% |
| Property, plant and equipment, net | 10,565 | 10,755 | +1.8% |
| Acquisition-related intangible assets, net | 15,838 | 18,606 | +17.5% |
| Goodwill | 49,362 | 54,832 | +11.1% |
| Total assets | 110,343 | 113,174 | +2.6% |
Two changes define the first half. The cash drawdown of $5,788 million paid for acquisitions ($8,872 million net of cash acquired, per the cash flow statement) and $4,000 million of share repurchases — the latter double the $2,000 million bought back in the same period of 2025. Those two outflows together exceeded first-half operating cash flow ($3,317 million) and new debt issuance ($5,238 million) combined.
The second change is structural. Goodwill and acquisition intangibles rose $8,238 million and now represent 64.9% of total assets, up from 59.1% at year end. Goodwill alone stands at 104.1% of Thermo Fisher's book equity, against 92.4% six months earlier. The company is now carrying more purchased goodwill than shareholder capital, which raises the stakes on any future impairment test.
Working capital discipline held up. Receivables grew 6.2% and inventories 3.7%, both slower than the 8.4% first-half revenue growth — and both balances absorbed acquired Clario assets, so the organic build was slower still. Lease exposure remains immaterial to the story: finance lease liabilities were $264 million against $213 million, a rounding error next to $42.5 billion of financial debt.
Refinancing risk is manageable in timing but adverse in price. Short-term obligations and current maturities were $3,368 million, roughly 8% of the $42,592 million of borrowings at par. A $5.00 billion revolving credit facility expires January 7, 2028 and was undrawn at quarter end (Note 3).
1-2. Debt structure — financial versus operating liabilities
Financial debt (borrowings at carrying value plus finance leases) rose 8.0%, from $39,385 million to $42,548 million. Net of cash and short-term investments, the move is far larger: net debt climbed 31.4%, from $29,280 million to $38,484 million.
The financing mix is the interesting part. Per the debt table in Note 3, Thermo Fisher issued four US dollar tranches in 2026 — $1,000 million at a 4.215% coupon due 2031, $750 million at 4.550% due 2033, $1,300 million at 4.902% due 2036, and $750 million at 5.546% due 2046, totalling $3,800 million at par. It also issued five Swiss franc tranches dated March 3, carrying coupons of 1.76% to 2.11% and totalling $1,432 million. The company raised just over a quarter of its new money in Swiss francs, at a weighted-average coupon of about 1.9% against roughly 4.8% on the dollar tranches — under half the dollar cost.
Against that, two cheap euro notes matured during the half — a 3.20% issue due January 21 and a 1.40% issue due January 23, together $1,409 million at year end, both now repaid. This is the refinancing arithmetic to watch: legacy euro, yen and franc paper carries coupons under 2%, while new dollar funding costs above 4%. Interest expense was flat in the quarter at $401 million versus $404 million, but that stability is temporary — six-month interest expense already rose to $755 million from $707 million.
Operating liabilities were essentially unchanged at $12,746 million versus $12,839 million. Accounts payable fell 9.8% and accrued payroll fell 15.1%, offset by higher contract liabilities and other accruals — the latter inflated by $375 million of contract liabilities assumed with Clario (Note 2).
1-3. Capital structure
Paid-in capital (common stock plus capital in excess of par) was $19,316 million against $19,008 million. Retained earnings rose 5.1% to $62,194 million. Yet total Thermo Fisher shareholders' equity fell 1.4%, from $53,407 million to $52,679 million.
The reason is treasury stock, which expanded by $4,061 million to $26,370 million. Buybacks consumed more capital than six months of earnings created ($3,018 million of retained-earnings growth). This is a deliberate choice, not distress — but it means the equity base shrank in the same six months the company added $9.1 billion of acquired assets.
2. Income Statement
2-1. Core performance
| Item | Q2 2025 ($M) | Q2 2026 ($M) | Change % |
|---|---|---|---|
| Product revenues | 6,249 | 6,823 | +9.2% |
| Service revenues | 4,605 | 5,171 | +12.3% |
| Total revenues | 10,855 | 11,994 | +10.5% |
| Gross profit | 4,409 | 4,882 | +10.7% |
| Gross margin (%) | 40.6 | 40.7 | — |
| Operating income | 1,834 | 2,087 | +13.8% |
| Operating margin (%) | 16.9 | 17.4 | — |
| Net income attributable to TMO | 1,617 | 1,736 | +7.4% |
| Diluted EPS ($) | 4.28 | 4.68 | +9.4% |
Operating leverage was 1.31 — each 1% of revenue growth produced 1.31% of operating income growth. That is real but modest for a company of this margin profile.
The gap between operating income (+13.8%) and net income (+7.4%) is the acquisition's hidden cost, though the bridge has an offset worth naming. Interest income fell 30%, from $297 million to $207 million, because the cash pile that generated it went to Clario. Against the $253 million operating gain, that $90 million loss, a $75 million higher tax charge and a $17 million adverse move in equity-method results were only partly cushioned by a $50 million favourable swing in other income (from $19 million of expense to $31 million of income) and $3 million less interest expense. Pretax income rose $215 million to $1,924 million — a 12.6% gain, well short of the operating line's 13.8%. Selling the balance sheet's cash cushion has an income statement price, and this quarter shows it.
Diluted EPS grew faster than net income because the share count fell 1.9%, from 378 million to 371 million.
The effective tax rate was 8.68% versus 5.38%, still far below the 21.0% US statutory rate. For the six months, the tax-rate reconciliation shows foreign tax effects reducing the rate by 11.8 percentage points, against 2.2 points a year earlier — worth roughly $358 million of pretax income, a benefit that flatters reported earnings and is not a durable operating result.
A note on adjusted figures. Thermo Fisher's non-GAAP reconciliation shows adjusted EPS of $6.03 against GAAP EPS of $4.68 — a 29% premium. Adjusted operating income of $2,735 million excludes four items from the GAAP $2,087 million: $485 million of acquisition-related intangible amortization, $98 million of restructuring, $36 million of SG&A adjustments and $28 million of cost-of-revenues adjustments. The largest exclusion is amortization, which is a direct and recurring consequence of the acquisition strategy. Clario added $3,796 million of definite-lived intangibles amortizing over a weighted-average 15 years — roughly $250 million a year of additional charge — so this "excluded" cost will keep growing. All analysis above uses GAAP figures.
2-2. Fixed versus variable cost leverage
The margin improvement did not come from production economics. Gross margin was effectively flat, contributing just 0.09 percentage points. The full +0.50 point operating margin gain decomposes as follows: SG&A leverage +0.26 points (SG&A fell to 19.45% of revenue from 19.71%), R&D leverage +0.21 points (3.03% from 3.24%), gross margin +0.09 points, less restructuring drag of 0.06 points.
In other words, nearly all of the margin expansion came from holding fixed costs down while revenue grew — including acquired revenue. R&D spending rose only 3.4% in the quarter ($364 million from $352 million) and 0.7% across the half, against revenue growth of 10.5% and 8.4%. Under US GAAP all R&D is expensed immediately rather than capitalized, so this is a clean read. But a research tools company growing R&D at a fraction of its sales rate is converting future capability into present margin. That is worth tracking.
3. Cash Flow
Six-month figures, as presented in the filing.
| Item | H1 2025 ($M) | H1 2026 ($M) | Change |
|---|---|---|---|
| Net cash from operating activities | 2,122 | 3,317 | +56.3% |
| Net cash used in investing activities | (815) | (8,797) | — |
| Net cash used in financing activities | (1,093) | (478) | — |
| Cash, equivalents and restricted cash, end of period | 4,603 | 4,096 | -11.0% |
Free cash flow (operating cash flow less capital expenditure) was $2,491 million against $1,466 million, up 69.9%. Capital expenditure rose to $826 million from $656 million, or 3.6% of revenue from 3.1% — a moderate step-up consistent with maintenance plus capacity, not a heavy build cycle.
Earnings quality improved sharply. Operating cash flow covered 0.98 times net income, against 0.68 times a year earlier. The improvement came from working capital, which consumed $1,537 million versus $2,151 million, plus higher non-cash depreciation and amortization of $1,553 million versus $1,391 million. A ratio near 1.0 is healthy; the prior-year 0.68 was the anomaly.
Investing activities also included $481 million from terminating cross-currency interest rate swaps and $187 million from swap interest settlements — $668 million of financing-adjacent cash that helped fund the deal without appearing as debt.
Capital returns exceeded internal generation. Buybacks of $4,000 million and dividends of $337 million totalled $4,337 million against $2,491 million of free cash flow — 174% of FCF, up from 158% a year earlier. Combined with the acquisition, the shortfall was covered by $5,238 million of new debt issuance and the cash balance.
4. Issues Worth Watching
Guidance went up, but on the adjusted basis. On the July 23 call management raised full-year 2026 revenue guidance to $47.4–48.1 billion (6–8% reported growth) and adjusted EPS to $24.93–25.33 (9–11% growth), with organic growth of about 4%, up from a prior 3–4% range. Two caveats sit inside that raise. First, full-year organic of ~4% against 5% delivered in Q2 implies no further acceleration in the second half. Second, the EPS guide is struck on the adjusted basis that excludes the acquisition amortization discussed above — the same charge Clario is about to enlarge.
Backlog gives visibility. Remaining performance obligations stood at $29.70 billion at quarter end, with 52% expected to convert within twelve months (Note 1). The rest relates to contract manufacturing, clinical research and extended warranties running three to five years. Against annualized first-half revenue of about $46.0 billion, that is roughly eight months of forward coverage — solid visibility, though the majority of it converts within a year and must be continually replenished.
Analytical Instruments is the cleanest recovery signal. Segment revenue grew 6.9% to $1,847 million — and the segment table attributes 7 points of that to organic growth, with zero from acquisitions and zero from currency, the only segment where both contributed nothing. Segment income jumped 30.5% and margin expanded 4.2 points to 23.0%. Electron microscopy led, up $55 million, with chromatography/mass spectrometry up $37 million and chemical analysis up $26 million. Specialty Diagnostics was also acquisition-free (6% reported = 5 points organic, 1 point currency), so the purchased growth is concentrated in the other two segments rather than spread across the business.
| Segment (Q2, incl. intersegment) | Revenue 2025 | Revenue 2026 | Rev Δ | Income 2025 | Income 2026 | Margin Δ |
|---|---|---|---|---|---|---|
| Life Sciences Solutions | 2,499 | 2,815 | +12.6% | 919 | 1,041 | 36.8% → 37.0% |
| Analytical Instruments | 1,728 | 1,847 | +6.9% | 325 | 424 | 18.8% → 23.0% |
| Specialty Diagnostics | 1,134 | 1,205 | +6.3% | 306 | 334 | 27.0% → 27.7% |
| Lab Products & Biopharma Services | 5,995 | 6,693 | +11.6% | 825 | 936 | 13.8% → 14.0% |
Segment revenues include intersegment sales; eliminations of $565 million reconcile to consolidated revenue of $11,994 million.
Life Sciences growth is mostly purchased. Reported revenue rose 13%, but the segment table splits it 9 points acquisitions, 1 point currency, 3 points organic. In the revenues-by-business disclosure, BioProduction grew to $941 million from $745 million (+26.3%), helped by the filtration and separation business bought from Solventum on September 1, 2025. Meanwhile biosciences revenue declined 1.4%, to $1,060 million from $1,075 million. The segment's headline masks a soft core.
The Clario deal is almost entirely intangible. Total consideration was $9,098 million — $5,806 million cash, $3,180 million of settled debt, $121 million payable and $108 million contingent, less $117 million of cash acquired. Against that, goodwill of $5,934 million and intangibles of $3,796 million total $9,730 million, or 107% of the price. Tangible net assets were negative after a $645 million deferred tax liability. The filing states plainly that the goodwill is not tax deductible, so there is no cash tax shield to offset the premium paid: the entire $5.9 billion sits on the balance sheet carrying impairment risk, while the $3.8 billion of intangibles grinds through GAAP earnings for the next 15 years. The purchase price allocation is also preliminary and subject to adjustment, particularly for intangibles, contract liabilities and the related deferred taxes — so the split between goodwill and amortizing assets can still move.